Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Schedule of Discount Rates Utilized, Active Claims and Total Black Lung Liabilities, Expected Aggregate Undiscounted Amount and Annual Black Lung Payments and (Benefit) Expense

The following table summarizes discount rates utilized, active claims and total black lung liabilities:


	December 31,
	2025			2024
	(Dollars in millions)
Discount rate(1)	4.5		%	4.5		%
Active claims	48			57
Total black lung liability, discounted(2)	$	12.6		$	13.7
Total black lung liability, undiscounted	$	23.4		$	25.3

(1)The discount rate is determined based on a portfolio of high-quality corporate bonds with maturities that are consistent with the estimated duration of our black lung obligations. A decrease of 25 basis points in the discount rate would have increased black lung expense by $0.4 million in 2025.

(2)The current portion of the black lung liability was $0.9 million and $1.0 million at December 31, 2025 and 2024, respectively, and was included in accrued liabilities on the Consolidated Balance Sheets.

The following table reconciles the expected aggregate undiscounted amount to amounts recognized in the Consolidated Balance Sheets:


	December 31,
	2025		2024
	(Dollars in millions)
Black lung liability, undiscounted	$	23.4	$	25.3
Impact of discounting	(10.8)		(11.6)
Black lung liability, discounted	$	12.6	$	13.7

The following table summarizes the annual black lung payments and (benefit) expense:


	Years Ended December 31,
	2025		2024		2023
	(Dollars in millions)
Payments(1)	$	1.0	$	40.4	$	5.4
(Benefit) expense(2)	$	(0.1)	$	(4.1)	$	5.5

(1)Payments for the year ended December 31, 2024 represent $4.4 million of black lung benefit payments made by the Company and the $36.0 million payment made to the DCMWC related to the regulatory exemption detailed above.

(2)The benefit for the year ended December 31, 2024 includes $5.4 million of accretion expense of the black lung liability and a $9.5 million gain related to the regulatory exemption detailed above. The $9.5 million gain is included in selling, general and administrative expense on the Consolidated Statements of Operations.

Schedule of Expected Payments and Aggregate Amount of Other Commitments

Expected payments for each of the five succeeding years and the aggregate amount thereafter as of December 31, 2025:


	(Dollars in millions)
2026	$	0.9
2027	0.8
2028	1.3
2029	1.0
2030	0.9
2031-Thereafter	18.5
Total	$	23.4

SunCoke Energy, Inc. 10-K